Reimagining biomarkers with RNA + AI:
Precision oncology for every target, drug, & patient

We transform transcriptomic data into actionable patient subgroups and treatment recommendations

Reimagining biomarkers with RNA + AI: RNA-Seq data, Genialis Supermodel, Mechanism-defined biologies, Clinically relevant subtypes

We develop accurate and informative RNA biomarkers that cover the breadth of cancer biology.

The two key ingredients are:

Our proprietary methodology for discovering and developing biomarkers

Our proprietary AI foundation model of cancer biology

RNA Biomarkers

We develop biomarkers that capture complex cancer biology from gene expression data, transforming raw RNA-seq data into actionable insights with predictive AI. Our mission is to help partners understand how their molecule works, and just as importantly, when it doesn’t.

A New Approach to Biomarkers
We see biomarkers as more than just diagnostic tests, they are measurable characteristics of health or disease, unlocking key insights into drug mechanisms, patient responses, and treatment durability. Whether delivered as an algorithm, an interactive tool, or a regulatory-ready software package, their true value lies in the answers they provide.

Why RNA-seq?
RNA-seq offers a highly multidimensional, phenotypic view of tumor biology, capturing more detail than DNA alone. It’s commoditized, reliable, and cost-efficient, making it an ideal tool for precision medicine.

Cancer patient and complex biology

Artificial Intelligence: Genialis™ Supermodel

The Genialis Supermodel is a large molecular model trained on a vast set of globally diverse RNA sequencing data. 

The Supermodel deciphers the underlying biologies of cancer, revealing critical states and processes. By minimizing bias and transforming thousands of data points into concise, signature-based scores, it supports the creation of biomarker algorithms. These algorithms help categorize patients, predict responses to specific treatments, and guide more informed decisions for non-responders.

Data model

Introducing Genialis™ krasID

The world’s first biomarker to predict tumor response and clinical benefit to KRAS-targeted therapeutics 

Featured Partners